ArticlePLoS neglected tropical diseases2022
Hypnozoite depletion in successive Plasmodium vivax relapses.
Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- Population heterogeneity in Plasmodium vivax relapse risk.PLoS neglected tropical diseases · 2022Trial
- Malaria serology for surveillance, insights into immunity, and vaccine development.Infection and immunity · 2026Review
- Predicting Risk of Plasmodium Vivax Microscopy-Detected Episodes Using Serological Markers in Patients With Plasmodium falciparum Malaria: A Multicountry Diagnostic Performance Evaluation.The Journal of infectious diseases · 2026Article
- Determinants of time to malaria treatment-seeking behaviour among caregivers of children under five in Uganda: a case study of Apac district.Malaria journal · 2026Article
- UnderstandingiScience · 2026Article
- High genetic diversity, clonal activation of hypnozoites and relapse of Plasmodium vivax isolates in low-transmission setting of Ethiopia.Research square · 2026Article
- The probability of Plasmodium vivax acute illness following primary infection and relapse in Papua New Guinea.PLoS neglected tropical diseases · 2025Article
- Applying novel Plasmodium Vivax serological exposure markers to quantify residual malaria transmission in the Philippines through repeated health facility surveys: the SMaRT study protocol.BMC infectious diseases · 2025Article
- Tracing the origins of Plasmodium vivax resurgence after malaria elimination on Aneityum Island in Vanuatu.Communications medicine · 2024Article
- Putative Contribution of 8-Aminoquinolines to Preventing Recrudescence of Malaria.Tropical medicine and infectious disease · 2023Article
- Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication.Tropical diseases, travel medicine and vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 2 countries.
Funding
Abstract
Genotyping Plasmodium vivax relapses can provide insights into hypnozoite biology. We performed targeted amplicon sequencing of 127 relapses occurring in Indonesian soldiers returning to malaria-free Java after yearlong deployment in malarious Eastern Indonesia. Hepatic carriage of multiple hypnozoite clones was evident in three-quarters of soldiers with two successive relapses, yet the majority of relapse episodes only displayed one clonal population. The number of clones detected in relapse episodes decreased over time and through successive relapses, especially in individuals who received hypnozoiticidal therapy. Interrogating the multiplicity of infection in this P. vivax relapse cohort reveals evidence of independent activation and slow depletion of hypnozoites over many months by multiple possible mechanisms, including parasite senescence and host immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.